The aim of the study is to analyse gene typing with the use of the microarray technique (HG-Ul33A, Affymetrix), differentiating colorectal cancer tissues from tissues assessed histopathologically as healthy ones among a panel of 93 mRNA of gene encoding proteins involved in the activation of cellular signal transduction pathways by insulin-like growth factors. The study was conducted on a group of 8 colorectal cancer patients. Frozen tumor and healthy specimens from the patients were used in molecular tests. Transcript IGF2 differentiated cancer from healthy tissue. Among the genes participating in the cascade of signal transfer in cells activated by IGF, GRBlO, PIK3R3, PIK3Rl, and IRSl were qualified as differentiating transcripts. IRSl indicated over-expression in tumour. Transcript SMAD2 showed a significant changed in tumour samples (increased expression).
Numerous epidemiological studies have proved that insulin-like growth factors play an important role in cancer development (1-3). There are ongoing studies aimed at defining the correlation between the expression of endogenous IGFI and the level of histopathological malignancy or cancerous disease progression. It is also being studied which ofthe IGF can be a marker of early and clinically asymptomatic disease (4) .
Insulin-like growth factors exert their biological impact by the influence on specific receptor proteins. As shown by previous research studies, insulin (INS) influences primarily metabolic effects (transportation of glucose, synthesis of glycogen and proteins) by insulin receptor (lR), and IGFl through IGFlR plays a role in the synthesis of nucleic acids, proliferation and apoptosis inhibition, while IGF2 is subject to degradation when it attaches to the insulin receptor (5) .
Signalling pathways activated by IGF factors lead to various molecular effects in the cell. IGFI R is activated by IGFI but also, to a smaller extent, by IGF2 (6) . Then both factors have to be considered as factors leading to proliferation disorders and cell apoptosis. INS activates a transmembrane signal, not only by its receptor but also by IGFIR. Therefore, it becomes a growth factor that can play an important role in transformation to cancer. The key role in the processes of proliferation and apoptosis of cells is therefore played by IGFIR, which displays activeness of tyrosine kinase. Activation of IGF I R initiates the processes of cell splitting by its influence on the cell cycle. It influences the transfer from the GO to G I phase of the cell cycle by p70S6K (ribosomal kinase) (7) . Through cyclin DI, it initiates the processes of splitting and regulates the transfer from the G I to S phase. IGF IR stimulates expression of cyclin D I both through the Raf/MAPI ERK pathway and also the PI-3K/Akt pathway (8) . IGF IR plays a regulating role in the transfer from the G2 to M phase, probably by growth of cyclin A and B and synthesis of cdc2 (9) .
The aim of the study is to analyse the diversity of expression profile of gene coding proteins of signal cascades activated by IGF in samples of tumour and healthy tissue in colorectal cancer patients.
MATERIALS AND METHODS

Materials
The study was conducted on a group of colorectal cancer patients in various stages of cancer (clinical and pathologic stage, TNM) and with diverse body mass indexes (Tables I, II ). Eleven transcriptomes, including 8 samples of tumour and 3 of healthy tissue, were accepted for comparative analysis in the Microarray Suite Affymetrix programme. All the patients provided written informed consent to participate in the study.
Methods
The tissue material for transcriptome tests, collected during surgery, was immediately put in sterile tubes with RNAlater™ (Sigma) in the amount of 10 JlI per I mg of the tissue (200 JlI RNAlater™ per 20 mg of the tissue) and after a one-day incubation at room temperature it was frozen in -80°C.
The analysis of the expression profile of genes coding proteins of signal cascades activated by insulin-like growth factors in the samples of colorectal cancer and healthy tissue was conducted with the oligonucleotide microarray technique with application of HG_UI33A plates (Affymetrix). The analysis started with comparison ofthe reports generated in the Microarray Suite Affymetri x programme directly after making out the fluorescence signals on the microarray. On the basis of the parameters characterizing the distribution of fluorescence signals on the plate, according to the manufacturer's instructions, II transcriptomes were accepted for comparative analysis (8 of cancer tissue and 3 of healthy tissue). The healthy specimens were also collected from the cancer patients, but they had undergone histopathological verification.
The comparative analysis of transcriptomes selected for the tested samples started with grouping oftranscriptomes by data clustering (hierarchical grouping with application of Tchebyshev distance and Ward's method), and the conformity of grouping was assessed on the basis of clinical, histopathological and molecular characteristics. The transcriptomes which were qualified to the same group regardless of the applied criteria for classification (clinical, histopathological or molecular) were selected for comparative analysis. The genes differentiating between the healthy and tumour tissue were typed among 93 transcripts related to the signal pathway activated by IGF on the basis of parameter signal log ratio (SLR) and the statistical analysis conducted in the significance analysis of microarrays (SAM) programme, in which modification of t test with use of permutation was applied, increasing the test reliability for a small frequency group with numerous attributes, just like in microarrays.
RESULTS
The comparative analysis ofmRNAconcentration profile in the healthy and tumour samples of patients with stage I-IV cancer (TNM) started with grouping of transcriptomes with Ward's method with application of Tchebyshev distance for 22 283 mRNA with application of HG_UI33A plates. The obtained results indicated clear differentiation of healthy transcriptomes from samples of I and II, and III and IV except for samples BIII6 and B I, which were excluded from further comparative analysis. The transcriptome BIII6 was grouped within cancer samples in levels I and II of clinical progression, while Bl was grouped with BII sample (tumour and healthy tissue of the same patient), which reflects some already existing molecular changes without any histopathological confirmation of cancerous changes in the tissue (Fig. I) .
Taking into account various stages of clinical and pathologic stages of colorectal cancer in the study group, four transcriptome groups were chosen for a comparative analysis aimed at searching for transcripts of genes differentiating colorectal cancer and healthy tissues (Table II) changes for differentiating genes was assessed on the basis of the indicators: 'score' and 'q-value'. The obtained results prove significant differentiation of the transcription activity of genes depending on the level of progression of cancerous changes. Transcript IGF2, GRBlO, PIK3R3, PIK3Rl. IRSl differentiated cancer from healthy tissue (over-expressed). Transcript SMAD2 showed a significant change in tumour samples (increased expression) (Tables III,  IV) .
DISCUSSION
The connection of cancer with the system of insulin-like growth factors has to be considered as a dynamic and changeable system in relation to the external and internal environment. For instance, it is necessary to study the growth factor-receptor(s) dependency. One cannot omit the presence ofbinding proteins and protheases, as well as the influence of other hormone and growth factors and cytokines (10) . Cancer process is a series of molecular changes that are effects of interaction of a cell and its environment. Such processes as angiogenesis, Iymphangiogenesis, cell motility, proliferation and cell apoptosis are also important. The IGFaxis can play a role in all the above-mentioned processes. IGF participates in the process of angiogenesis through a few mechanisms. On one hand, IGFI and IGF2 stimulate migration and differentiation of cells (II). Simultaneously, IGF I and insulin influence the processes of angiogenesis by their impact on VEGF and endoteline -I (12) . As stated, synthesis ofIGF I is connected with hypoxemia, which was confirmed on cell lines of hepatocellular carcinoma. The IGF system also co-operates with the kinase receptor EGFR, it forms a hybrid IGFIR/EGFR, then the receptor can be activated by both growth factors.
The IGF system plays a role in regulation of metalloproteinases (MMP) and can influence tumour growth. Array of metalloproteinases is produced as inactive proenzimes which require activation by proteolytic processes. As stated, MMP-14 is the largest activator of MMP-2 and is activated by IGFIR through the PI-3K/Akt/mTOR pathway (13) . In cells in which IGF IR regulates expression of MMP, metalloproteinases can in turn decrease the bioavailability of IGF by degradation of IGFBP-3 and IGFBP-5. The studies were conducted on cell cultures on lines of fibroblasts and osteoblasts. The latest reports indicate that MMP-7 participates in proteolytic processes of all IGFBP and it then becomes a promoter of IGF I R, launching phosphorylation and signalling processes related to that receptor (14) (15) . Transcript GRBIO and the remammg differentiating mRNA ofgene code proteins of signal paths started by fGF1R, leads to disorder ofapoptosis (PIK3R3, PIK3RI, GRB 10, SOCS3), to disorders of proliferation (IRS I, GRB I0, SOCS3), and activation ofthe pathway Ras/Raf/Mek influences the cell cycle by cyclin D I.
In the present study, the analysis of microarrays of patients with colorectal cancer indicated that transcript IGF2 differentiates cancer from healthy tissue. Similar results were obtained by Li et al. (16) , confirming the analysis ofRT-PCR. Among the genes participating in the cascade of signal transfer in cells activated by IGF, PIK3R3, PIK3RI, and IRSI were qualified as differentiating transcripts. Proteins of these genes take part in transmission of the signal leading to proliferation and inhibition of apoptosis, but transduction of signal can be related also to other receptors and ligands. Among the transcripts differentiating cancer from healthy tissue, IRS I indicated over-expression in tumour.
IRS 1-2 proteins play an important role in signal transmission through the PKB/Akt pathway leading mainly to inhibition of apoptosis. Expression of IRS I was found in many solid type carcinomas: in breast cancer, adrenal cortex cancer and sarcomas. In the study of Chang et al. (17) , expression of the gene IRSI in 27/34 tumours (QRT-PCR) was found and the blocking of IRS I signal on cell lines led to inhibition of tumour growth. The study proves that one of the therapeutic aims of the pathway related to IGF can also be adjustment of low-molecularweight inhibitors blocking tyrosine kinase of IRS I. Of course, one cannot forget that the IRS I pathway also plays an important role in healthy cells and activation of that pathway is responsible for the metabolism of carbohydrates and cell adhesion.
The analysis of 22 283 mRNA transcripts provides knowledge and interpretation possibilities but, at the same time, constitutes a challenge for accurate definition of results and analyses. The analysis of expression profile of gene coding proteins of cell signal pathways is the method of "transcription patterns" study, not protein activity (18) . Initially, it was believed that the effectiveness of antibody application directed to the EGFR in cancer treatment would be proportional to the level of receptor expression. However, the conducted research did not indicate any dependency between the primary expression of EGFR assessed on the basis of immumohistochemical tests of archival tissue samples and the response to treatment (19) . Activation of EGFR can take place transversely with other receptors, for example with the receptor conjugated with the protein G and with the receptor IGFIR, which was confirmed on the cell lines of head and neck squamous cell carcinoma (HNSCC). Combination treatment, simultaneous application of antibodies for EGFR and IGF 1R, as well as for HER2, causes stronger inhibition of proliferation of cells, which was confirmed by tests on cell lines (20) . It is important to conduct further studies in order to confirm the possibility of application of insulin-like growth factors in targeted therapy and prophylaxis.
